Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913579 | 0.84 | MAPT (1.00) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6171184 | 0.81 | RAB9A (0.72) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4395617 | 0.76 | MAPT (0.61) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6032690 | 0.76 | MAPT (0.61) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25202713 | 0.75 | MAPT (0.60) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30500214 | 0.75 | MAPT (0.60) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL916067 | 0.74 | MAPT (0.65) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL913448 | 0.72 | ELANE (0.78) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4187104 | 0.71 | MAPT (0.55) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL914400 | 0.71 | MAPT (1.00) | MAPTNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | claimed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | claimed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1631295-B1 | USE OF CONDENSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | AREXIS AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | MAPT 2054/4885NPC1 4151/4885RAB9A 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.